Back to results
US 2020/0392114 A1Published application
SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZINE-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
AssigneeFORMA Therapeutics, Inc.
InventorsGeorge P. LUKE, Stephen HUBBS, Matthew W. MARTIN, Shawn E.R. SCHILLER, Robert WENSLOW, Yawei SHI, Jun HUANG
Life of this patent
Estimating the term…
Abstract
The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone:
Claims21
A solid form of Compound 1 free base:
- wherein the solid form is selected from the group consisting of Mixture A, Form B, Form C, Form X, and Form Z.
A composition comprising Compound 1 free base Mixture A:
- wherein Mixture A is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
A pharmaceutical composition comprising a solid form of Compound 1 free base:
- and a pharmaceutically acceptable carrier, wherein the solid form of Compound 1 is Form B and is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
A solid form of Compound 1:
- wherein the solid form is the form that would be obtained by a process comprising:
- suspending at least one of Mixture A, Form C, and Form X of Compound 1 in a solvent selected from a group consisting of ethyl acetate (EtOAc), acetonitrile (ACN), heptane, isopropyl alcohol (IPA), and ethanol (EtOH) to provide a slurry;
- and
- maintaining the slurry for a period of at least 5 hours to afford the solid form of Compound 1.
1 more element
Dependencies are inferred from the claim text.